{"nctId":"NCT01195467","briefTitle":"Atripla to Raltegravir Switch Study for CNS Toxicity","startDateStruct":{"date":"2010-10"},"conditions":["HIV Infection"],"count":40,"armGroups":[{"label":"All Subjects Truvada/Raltegravir","type":"EXPERIMENTAL","interventionNames":["Drug: Truvada/Raltegravir"]}],"interventions":[{"name":"Truvada/Raltegravir","otherNames":["Truvada® = tenofovir + emtricitabine","Atripla® = tenofovir + emtricitabine + efavirenz","Raltegravir = isentress"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. is male or female aged 18 years or above\n2. has a documented HIV-1 infection\n3. has signed the Informed Consent Form voluntarily\n4. is willing to comply with the protocol requirements\n5. has an HIV-plasma viral load at screening \\<50 copies/mL\n6. has a CD4 cell count at Screening \\>50 cells/mm3\n7. has been on a stable ART, with at least 3 licensed agents, one of which being EFV, for at least 12 weeks at Screening, and has been on Atripla for at least 4 weeks at screening; the subject must be willing to stay on treatment until Baseline\n8. estimated glomerular filtration rate (by MDRD or CG methods) \\>50 ml/min.\n9. has symptomatic toxicity associated with EFV after at least 12 weeks of therapy\n10. if female and of childbearing potential, she is using effective birth control methods (as agreed by the investigator) and is willing to continue practising these birth control methods during the trial and for at least 30 days after the end of the trial (or after last intake of investigational ARVs); Note: Women who are postmenopausal for least 2 years, women with total hysterectomy, and women who have a tubal ligation are considered of non-childbearing potential\n11. if a heterosexually active male, he is using effective birth control methods and is willing to continue practising these birth control methods during the trial and until follow-up visit\n\nExclusion Criteria:\n\n1. is infected with HIV-2\n2. is using any concomitant therapy disallowed as per SPC for the study drugs (section 5.2)\n3. has a currently active AIDS defining illness (Category C conditions according to the CDC Classification System for HIV Infection 1993) with the following exceptions (must be discussed with the sponsor prior to enrolment):\n\n   * Stable cutaneous Kaposi's Sarcoma (no pulmonary or gastrointestinal involvement other than oral lesions) unlikely to require systemic therapy during the trial period\n   * CD4 count less than 200 cells/mm3 Note: Primary and secondary prophylaxis for an AIDS defining illness is allowed\n4. has acute viral hepatitis including, but not limited to, A, B, or C\n5. has chronic hepatitis B and/or C with AST and/or ALT \\>5 x ULN Note: Subjects co-infected with chronic HBV or HCV can enter the trial if clinically stable and not expected to require treatment during the trial period.\n6. has received any investigational drug within 30 days prior to the trial drug administration\n7. Prior exposure to raltegravir or investigational integrase inhibitors\n8. Any tenofovir or emtricitabine associated resistance mutations\n9. No baseline resistance test available\n10. Clinically significant allergy or hypersensitivity to any trial medication excipients\n11. If female, she is pregnant or breastfeeding\n12. screening blood results with any grade 3 / 4 toxicity according to Division of AIDS (DAIDS) grading scale, except: asymptomatic grade 3 glucose, amylase or lipid elevation or asymptomatic grade 4 triglyceride elevation (re-test allowed).\n13. Clinical or laboratory evidence of significantly decreased hepatic function or decompensation: INR \\> 1.5 or albumin \\< 30g/L or bilirubin \\> 2.5 x ULN\n14. Resolution of their CNS toxicity between Screening and Baseline visits\n15. Any condition (including drug/alcohol abuse) or laboratory results which, in the investigator's opinion, interfere with assessments or completion of the trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Rate of Neuropsychiatric and Central Nervous System (CNS) Toxicity of Raltegravir Therapy After 4 Weeks on Treatment","description":"To assess the rate of neuropsychiatric and central nervous system (CNS) toxicity as measured from baseline to 4 weeks of raltegravir therapy as measured by sleep questionnaire \\& CNS toxicity (as determined by questionnaire based on efavirenz SPC and graded based on the ACTG adverse event scale)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"The Rate of Neuropsychiatric and Central Nervous System (CNS) Toxicity of Raltegravir Therapy After 12 Weeks on Treatment","description":"The rate of neuropsychiatric and central nervous system (CNS) toxicity as measured after 12 weeks of raltegravir therapy as measured by :\n\n* Sleep questionnaire\n* CNS toxicity (as determined by questionnaire based on efavirenz SPC and graded based on the ACTG adverse event scale)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 12 in CD4+ Count After 12 Weeks of Raltegravir","description":"Change from baseline to week 12 in CD4+ count after 12 weeks of raltegravir having switched from efavirenz-containing therapy","classes":[]},{"type":"SECONDARY","title":"Proportion of Patients With Viral Load < 50 Copies/mL and <400 Copies/ml at Weeks 4 and 12 After Switching to Raltegravir","description":"To assess the proportion of patients with viral load \\< 50 copies/mL and \\<400 copies/ml at weeks 4 and 12 after switching to raltegravir","classes":[]},{"type":"SECONDARY","title":"Change in Fasting Lipids (Total Cholesterol and Subfractions and Triglycerides) After 4 and 12 Weeks of Raltegravir","description":"To assess the change in fasting lipids (total cholesterol and subfractions and triglycerides) after 4 and 12 weeks of raltegravir","classes":[]},{"type":"SECONDARY","title":"Proportion of Patients With Grade 2-4 Laboratory Parameters (Excluding Lipids) After 12 Weeks of Raltegravir Compared With Baseline","description":"To assess the proportion of patients with grade 2-4 laboratory parameters (excluding lipids) after 12 weeks of raltegravir compared with baseline","classes":[]},{"type":"SECONDARY","title":"Proportion of Patients With Grade 2-4 Non-CNS Adverse Events After 12 Weeks of Raltegravir Compared With Baseline","description":"To assess the proportion of patients with grade 2-4 non-CNS adverse events after 12 weeks of raltegravir compared with baseline","classes":[]},{"type":"SECONDARY","title":"Change From Baseline in Adherence From Baseline After 12 Weeks of Raltegravir as Measured by the Adherence Questionnaire: Medication Adherence Self-Report Inventory (M-MASRI)","description":"To assess the change from baseline in adherence from baseline after 12 weeks of raltegravir as measured by the adherence questionnaire: Medication Adherence Self-Report Inventory (M-MASRI)","classes":[]},{"type":"SECONDARY","title":"Change From Baseline of CNS Toxicity as Measured by Hospital Anxiety and Depression (HADS) Score (Baseline vs Week 12)","description":"To assess the change from baseline of CNS toxicity as measured by Hospital Anxiety and Depression (HADS) score (baseline vs week 12)","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":40},"commonTop":["Bilateral Arm Pain","Ichthyosis","Haematuria","Renal Colic","Cellulitis"]}}}